Drugs that contain Avibactam Sodium; Ceftazidime
1. List of Avycaz drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7112592 | ALLERGAN | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
Jan, 2026
(2 years from now) | |
| US8471025 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Aug, 2031
(8 years from now) | |
| US9695122 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| US9284314 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| US8969566 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612087 | ALLERGAN | Heterocyclic compounds as inhibitors of beta-lactamases |
Nov, 2026
(3 years from now) | |
| US8835455 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Oct, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 25, 2020 |
| Generating Antibiotic Incentives Now (GAIN) | Feb 25, 2025 |
NCE-1 date: February, 2024
Market Authorisation Date: 25 February, 2015
Treatment: A method of treating bacterial infections in complicated intra-abdominal infection and complicated urinary tract infection, including pyelonephritis, patients comprising administering a bactericidally effective amount of avibactam sodium; A method of treating bacterial infections in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pnenumonia (habp/vabp) patients comprising administering a bactericidally effective amount of avibactam sodium; Method of treating bacterial infections
Dosage: POWDER;INTRAVENOUS
AVYCAZ family patents
22
United States
9
Japan
9
China
8
European Union
7
Korea, Republic of
7
Brazil
6
Spain
5
Hong Kong
5
Australia
5
Israel
5
France
4
Poland
4
Mexico
4
Slovenia
4
Argentina
4
Portugal
4
Russia
4
Canada
4
Denmark
3
Malaysia
3
Cyprus
3
Hungary
3
Norway
3
Taiwan, Province of China
3
Costa Rica
2
Austria
2
Morocco
2
Ukraine
2
Yugoslavia
2
Germany
2
OA
2
South Africa
2
Croatia
2
EA
2
Turkey
2
ME
2
New Zealand
2
Ecuador
1
Estonia
1
AP
1
Chile
1
Algeria
1
Lithuania
1
Slovakia
1
Uruguay
1
Jordan
1
Netherlands
1
Tunisia
1
United Kingdom
1
Colombia
1
Belgium
1
Peru
1
Bulgaria
1
Singapore
1
Czech Republic
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic